Skip to content
Search

Latest Stories

HSCC’s report set out steps to strengthen UK’s position in vaccination

The Health and Social Care Committee (HSCC) has undertaken an inquiry into prevention and has published its first report of the series which focuses on vaccination.

It has announced ten workstreams that will form the basis of inquiry, of which vaccination is one.


HSCC said: “The UK has long been one of the world leaders on vaccination - one of the most successful and cost-effective preventative tools available. However, if challenges around uptake and bureaucratic processes in clinical trial set-up are not addressed, there is a very real risk that the UK’s position as a global leader could be lost. This cannot be allowed to happen and in this report we set out some of the steps that we think will make a difference.”

It recommended a more flexible delivery model making use of a wider range of healthcare professionals.

“The NHSE vaccination and immunisation strategy must have a strong focus on tackling practical challenges that limit vaccination access, make best use of a wider array of professionals, empower local leaders to pursue ways of addressing uptake in their own areas, and to set out guidance and examples of best practice around how voices other than NHSE can communicate important messaging around vaccination programmes,” it suggested.

Malcolm Harrison, Chief Executive of the CCA said: “We welcome the Committee’s report on vaccination. Community pharmacy can be the home for all vaccinations. We have an amazing track record – over the 2022/23 winter vaccination programme, pharmacies administered a record-breaking  5m+ flu vaccinations.

The CCA’s prospectus1 estimates that the sector can free up a further 10m+ GP vaccination appointments annually, which would free up GP capacity.

Community pharmacy offers an accessible and convenient place for patients to receive vaccinations. In the longer term, we want to see community pharmacy involved in all vaccination programmes and helping to drive uptake, especially for those in deprived communities.”

Ben Lucas, Managing Director at MSD and ABPI Board member, submitted evidence to the inquiry on behalf of the ABPI. He said, “The UK has historically had a strong record on vaccination, so it is frustrating to see rates going in the wrong direction when better preventative measures could ease wider pressures on the NHS. To get back on track, we must look at the whole immunisation journey, from development, to assessment, through to getting vaccines to those who need them.

“Firstly, we must fix the slow and bureaucratic set up of clinical trials to streamline innovation. Next, we need to ensure our regulators and independent scientific advisers have the resources they need to properly assess new vaccines quickly. Finally, we need the right data and healthcare teams in place to deliver flexible vaccination services tailored to the needs of local communities and underserved populations.

“We welcome the Committee’s comprehensive report and look forward to seeing the forthcoming NHS vaccination strategy, which we hope will put these recommendations into action without delay.”

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less